Working… Menu

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00656578
Recruitment Status : Completed
First Posted : April 11, 2008
Last Update Posted : May 4, 2009
Information provided by:
Anesiva, Inc.

Brief Summary:

The primary purpose of this study is to compare the analgesic efficacy of a single intraoperative administration of 4975 vs. Placebo in the management of acute postoperative pain in patients undergoing bunionectomy.

Secondary objective of this study is to evaluate the safety and tolerability of a single intraoperative administration of 4975.

Condition or disease Intervention/treatment Phase
Pain Drug: 4975 Drug: Placebo Phase 3

Detailed Description:

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the US. A dose of 4975 will be evaluated against placebo in patients undergoing bunionectomy. Upon enrollment, patients will be randomized in a 1:1 ratio to receive either 4975 or placebo.

After the surgery, patients will be admitted to the clinical study site, where trained study personnel will monitor them for up to 48 hours. While at the clinical study site, patients will undergo safety and efficacy assessments. After discharge, patients will report pain severity daily through Day 14 via an interactive voice response system (IVRS). Also, safety and patient-reported outcome assessments will be performed at the Day 14 (Week 2) and Day 28 (Week 4) clinic visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy and Safety of a Single Intraoperative Administration of 4975 in Patients Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity
Study Start Date : March 2008
Actual Primary Completion Date : August 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Bunion

Arm Intervention/treatment
Experimental: 1
Drug: 4975
Single dose, solution

Placebo Comparator: 2
Drug, Single dose, solution
Drug: Placebo
Single dose, solution

Primary Outcome Measures :
  1. Evaluate efficacy of a single intraoperative administration of 4975 in the management of acute postoperative pain in patients undergoing bunionectomy [ Time Frame: Prospective ]

Secondary Outcome Measures :
  1. Evaluate safety and tolerability of a single intraoperative administration of 4975 [ Time Frame: Prospective ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged 18 years and older.
  • Planning to undergo unilateral transpositional first metatarsal osteotomy for correction of Hallux Valgus Deformity (referred to as bunionectomy in this protocol).

Exclusion Criteria:

  • Use of certain medications or having a medical condition that in the investigator's opinion could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments.
  • Diabetes mellitus with a known HbA1C > 9.5 or a history of prolonged uncontrolled diabetes.
  • Participated in another clinical trial or used an investigational product within 30 days prior to the planned bunionectomy surgery, or is scheduled to receive an investigational product other than 4975 while participating in the study.
  • Previously participated in a clinical study with 4975.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00656578

Layout table for location information
United States, California
Foot and Ankle Institute
Bakersfield, California, United States, 93311
United States, Maryland
Crossroads Research, Inc.
Owings Mills, Maryland, United States, 21117
United States, Texas
Scirex Research Center
Austin, Texas, United States, 78705
San Antonio Podiatry Associates, PC
San Antonio, Texas, United States, 78229
Hill Country Sports Medicine of Podiatric Surgery
San Marcos, Texas, United States, 78666
United States, Utah
Scirex Research Center
Salt Lake City, Utah, United States, 84117
Sponsors and Collaborators
Anesiva, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Denise Sharp - CRA, Anesiva, Inc. Identifier: NCT00656578    
Other Study ID Numbers: 114-08P
First Posted: April 11, 2008    Key Record Dates
Last Update Posted: May 4, 2009
Last Verified: May 2009
Keywords provided by Anesiva, Inc.:
Hallux Valgus Deformity
Surgery for Transpositional first metatarsal osteotomy - Bunionectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hallux Valgus
Foot Deformities
Musculoskeletal Diseases